Cargando…

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma

BACKGROUND: Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (combinations) are warranted. Simultaneously, risk as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Emde-Rajaratnam, Martina, Beck, Susanne, Benes, Vladimir, Salwender, Hans, Bertsch, Uta, Scheid, Christoph, Hänel, Mathias, Weisel, Katja, Hielscher, Thomas, Raab, Marc S., Goldschmidt, Hartmut, Jauch, Anna, Maes, Ken, De Bruyne, Elke, Menu, Eline, De Veirman, Kim, Moreaux, Jérôme, Vanderkerken, Karin, Seckinger, Anja, Hose, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684778/ https://www.ncbi.nlm.nih.gov/pubmed/38035078 http://dx.doi.org/10.3389/fimmu.2023.1286700

Ejemplares similares

Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial
por: Hose, Dirk, et al.
Publicado: (2019)

MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma
por: Stroh, Jacob, et al.
Publicado: (2022)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation
por: Merz, Maximilian, et al.
Publicado: (2017)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2023)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells
por: Lub, Susanne, et al.
Publicado: (2015)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial
por: Schmitt, Michael, et al.
Publicado: (2016)

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma
por: Merz, Maximilian, et al.
Publicado: (2019)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
por: Oudaert, Inge, et al.
Publicado: (2022)

The Glycome of Normal and Malignant Plasma Cells
por: Moehler, Thomas M., et al.
Publicado: (2013)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
por: Fan, Rong, et al.
Publicado: (2022)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients
por: Kriegsmann, Katharina, et al.
Publicado: (2019)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2020)

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age
por: Mai, Elias K., et al.
Publicado: (2021)

The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma
por: Maes, Anke, et al.
Publicado: (2019)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients
por: Weinhold, Niels, et al.
Publicado: (2021)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
por: Baertsch, Marc-Andrea, et al.
Publicado: (2021)

PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
por: Van der Vreken, A., et al.
Publicado: (2022)

Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells
por: Meißner, Tobias, et al.
Publicado: (2015)

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial
por: Weisel, Katja C., et al.
Publicado: (2019)

miRNAs in multiple myeloma – a survival relevant complex regulator of gene expression
por: Seckinger, Anja, et al.
Publicado: (2015)

P860: THE DE NOVO DNA METHYLTRANSFERASE DNMT3B PLAYS AN IMPORTANT ROLE IN MM CELL GROWTH, CLONOGENICITY AND DRUG RESPONSE
por: Muylaert, C., et al.
Publicado: (2022)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma
por: Fan, Rong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_278ion7673k4bp9hbdehaic47b